Cabazitaxel

Active ingredient: Cabazitaxel

In short: Cabazitaxel Injection is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

Forms & strengthsCabazitaxel Injection is supplied as a kit consisting of the following: Cabazitaxel injection: 60 mg/1.5 mL; a clear colourless to pale yellow or brownish-yellow viscous solution Diluent: 5.7 mL of 13% (w/w) ethanol in water; a clear colorless solution
LabelAccord Healthcare Inc.
Label updatedNov 04, 2024

What is Cabazitaxel used for?

Cabazitaxel Injection is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.

âš  Boxed warning (FDA's strongest warning)

Neutropenia: Neutropenic deaths have been reported. Monitor for neutropenia with frequent blood cell counts. Cabazitaxel Injection is contraindicated in patients with neutrophil counts of ≤1,500 cells/mm

3. Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m

2

.

Severe hypersensitivity: Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm. Severe hypersensitivity reactions require immediate discontinuation of the Cabazitaxel Injection infusion and administration of appropriate therapy. Patients should receive premedication. Cabazitaxel Injection is contraindicated in patients who have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80

[see

Dosage and Administration (2.1),

Contraindications (4), and

Warnings and Precautions (5.3)]

.

Cabazitaxel dosage

The recommended dose of Cabazitaxel Injection is based on calculation of the Body Surface Area (BSA), and is 20 mg/m

2 administered as a one-hour intravenous infusion every three weeks in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel Injection treatment.

A dose of 25 mg/m

2 can be used in select patients at the discretion of the treating healthcare provider

[see

Warnings and Precautions (5.1,

5.2),

Adverse Reactions (6.1), and

Clinical Studies (14)].

Primary prophylaxis with G-CSF is recommended in patients with high-risk clinical features. Consider primary prophylaxis with G-CSF in all patients receiving a dose of 25 mg/m

2

.

Premedicate at least 30 minutes prior to each dose of Cabazitaxel Injection with the following intravenous medications to reduce the risk and/or severity of hypersensitivity

:

antihistamine (dexchlorpheniramine 5 mg, or diphenhydramine 25 mg or equivalent antihistamine),

corticosteroid (dexamethasone 8 mg or equivalent steroid),

H

2 antagonist.

Antiemetic prophylaxis is recommended and can be given orally or intravenously as needed

.

Cabazitaxel Injection single-dose vial requires

two

dilutions prior to administration

.

Reduce or discontinue Cabazitaxel Injection dosing for adverse reactions as described in Table 1.

Toxicity | Dosage Modification

Prolonged grade ≥3 neutropenia (greater than 1 week) despite appropriate medication including granulocyte-colony stimulating factor G-CSF | Delay treatment until neutrophil count is > 1,500 cells/mm

3, then reduce dosage of Cabazitaxel Injection by one dose level. Use G-CSF for secondary prophylaxis.

Febrile neutropenia or neutropenic infection | Delay treatment until improvement or resolution, and until neutrophil count is > 1,500 cells/mm

3, then reduce dosage of Cabazitaxel Injection by one dose level. Use G-CSF for secondary prophylaxis.

Grade ≥3 diarrhea or persisting diarrhea despite appropriate medication, fluid and electrolytes replacement | Delay treatment until improvement or resolution, then reduce dosage of Cabazitaxel Injection by one dose level.

Grade 2 peripheral neuropathy | Delay treatment until improvement or resolution, then reduce dosage of Cabazitaxel Injection by one dose level.

Grade ≥3 peripheral neuropathy | Discontinue Cabazitaxel Injection

Patients at a 20 mg/m

2 dose who require dose reduction should decrease dosage of Cabazitaxel Injection to 15 mg/m

2

.

Patients at a 25 mg/m

2 dose who require dose reduction should decrease dosage of Cabazitaxel Injection to 20 mg/m

2. One additional dose reduction to 15 mg/m

2 may be considered

.

Mild hepatic impairment (total bilirubin > 1 to ≤1.5 x Upper Limit of Normal (ULN) or AST >1.5 x ULN): Administer Cabazitaxel Injection at a dose of 20 mg/m

2. …

How to take Cabazitaxel — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Educate patients about the risk of potential hypersensitivity associated with Cabazitaxel Injection. Confirm patients do not have a history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80. Instruct patients to immediately report signs of a hypersensitivity reaction

.

Bone Marrow Suppression

Inform patients that Cabazitaxel Injection decreases blood count such as white blood cells, platelets and red blood cells. Thus, it is important that periodic assessment of their blood count be performed to detect the development of neutropenia, thrombocytopenia, anemia, and/or pancytopenia

. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever to their healthcare provider.

Increased Toxicities in Elderly Patients

Inform elderly patients that certain side effects may be more frequent or severe

.

Importance of Prednisone

Explain that it is important to take the oral prednisone as prescribed. Instruct patients to report if they were not compliant with oral corticosteroid regimen

. …

Warnings & precautions

Do not take this medicine if: Cabazitaxel Injection is contraindicated in patients with:

neutrophil counts of ≤1,500/mm

3

history of severe hypersensitivity reactions to cabazitaxel or to other drugs formulated with polysorbate 80

severe hepatic impairment (total bilirubin > 3 × ULN)

Cabazitaxel is contraindicated in patients with neutrophils ≤1,500/mm

3

. Closely monitor patients with hemoglobin <10 g/dL.

Bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia may occur. Neutropenic deaths have been reported.

TROPIC Trial (Cabazitaxel 25 mg/m

2)

In the TROPIC trial with G-CSF administered only at the investigator’s discretion, 5 patients (1.3%) died from neutropenic infection (sepsis or septic shock); 4 of these patients died in the first 30 days of treatment. One additional patient’s death was attributed to neutropenia without a documented infection. Twenty-two (6%) patients discontinued cabazitaxel treatment due to neutropenia, febrile neutropenia, infection, or sepsis. Grade 3-4 neutropenia occurred in 82% of patients treated with cabazitaxel in the randomized trial

.

PROSELICA Trial (comparison of cabazitaxel 20 mg/m

2 versus 25 mg/m

2)

In the PROSELICA trial comparing two doses of cabazitaxel, primary prophylaxis with G-CSF was not allowed, but could be administered after development of neutropenia at investigators discretion. Eight patients (1%) on the 20 mg/m

2 arm and 15 patients (3%) on the 25 mg/m

2 arm died from infection; of these, 4 deaths on the 20 mg/m

2 arm and 8 deaths on the 25 mg/m

2 arm occurred within the first 30 days of treatment. …

Cabazitaxel side effects

The following serious adverse reactions are discussed in greater detail in another section of the label:

Bone Marrow Suppression

Increased Toxicities in Elderly Patients

Hypersensitivity Reactions

Gastrointestinal Adverse Reactions

Renal Failure

Urinary Disorders Including Cystitis

Respiratory Disorders

Use in Patients with Hepatic Impairment

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.

TROPIC Trial (Cabazitaxel 25 mg/m

2 compared to mitoxantrone)

The safety of cabazitaxel in combination with prednisone was evaluated in 371 patients with metastatic castration-resistant prostate cancer treated in the randomized TROPIC trial, compared to mitoxantrone plus prednisone.

Deaths due to causes other than disease progression within 30 days of last study drug dose were reported in 18 (5%) cabazitaxel-treated patients and 3 (<1%) mitoxantrone-treated patients. The most common fatal adverse reactions in cabazitaxel-treated patients were infections (n=5) and renal failure (n=4). The majority (4 of 5 patients) of fatal infection-related adverse reactions occurred after a single dose of cabazitaxel. Other fatal adverse reactions in cabazitaxel-treated patients included ventricular fibrillation, cerebral hemorrhage, and dyspnea. …

Drug interactions

Cabazitaxel is primarily metabolized through CYP3A

. Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase plasma concentrations of cabazitaxel. Avoid the coadministration of cabazitaxel with strong CYP3A inhibitors. If patients require coadministration of a strong CYP3A inhibitor, consider a 25% cabazitaxel dose reduction

.

About this medicine

Cabazitaxel Injection is an antineoplastic agent belonging to the taxane class that is for intravenous use. It is prepared by semi-synthesis with a precursor extracted from yew needles.

The chemical name of cabazitaxel is (2α,5β,7β,10β,13α)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxy carbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate.

Cabazitaxel has the following structural formula:

Cabazitaxel is a white to off-white powder with a molecular formula of C

45H

57NO

14 and a molecular weight of 835.93. It is lipophilic, practically insoluble in water and soluble in alcohol.

Cabazitaxel Injection 60 mg/1.5 mL is a sterile, non-pyrogenic, clear colourless to pale yellow or brownish-yellow viscous solution and is available in single-dose vials containing 60 mg cabazitaxel (anhydrous and solvent free) and 1.56 g polysorbate 80 (citric acid is used to adjust the pH of the polysorbate 80 between 3.2 to 3.6).

Each mL contains 40 mg cabazitaxel (anhydrous) and 1.04 g polysorbate 80. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ec6892c8-01e1-6a8b-e053-2995a90a956f. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate